Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study - 15/10/18
Funding sources: None. |
|
Conflicts of interest: Dr Yeung has been a speaker, consultant, and/or investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, and Takeda. Dr Shear has been a consultant and/or speaker for AbbVie, Actelion, Amgen, Celgene, Hospira, Janssen, Janssen Biotech, Lilly, Novartis, Sanofi, Genzyme, and Takeda. Dr Walsh has been a consultant for AbbVie, Amgen, Celgene, Janssen, and Lilly. Mr Georgakopoulos and Mr Ighani have no conflicts of interest to disclose. |
Vol 79 - N° 5
P. 953-956 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?